Journal
ALZHEIMERS RESEARCH & THERAPY
Volume 11, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13195-019-0485-0
Keywords
Alzheimer's Disease; Amyloid Peptides; A42; 40ratio; Biomarkers; Cerebrospinal Fluid
Categories
Funding
- Fujirebio Europe
- Innovative Medicines Initiative Joint Undertaking under EMIF from the European Union's Seventh Framework Programme (FP7/2007-2013) [115372]
- EFPIA companies
- Roche
- GE Healthcare
- Biogen
- AVID Radiopharmaceuticals
- Fujirebio
- Euroimmun
- Swedish Research Council
- European Research Council
- Knut and Alice Wallenberg Foundation
- Olav Thon Foundation
- UK Dementia Research Institute at UCL
- Swedish State Support for Clinical Research (ALFGBG)
Ask authors/readers for more resources
The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloid 42 (A(42)), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau(181)) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of A(42) to A(40) (A(42/40) Ratio) has been suggested to be superior to the concentration of A(42) alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF A(42/40) ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF A(42/40) ratio, rather than the absolute value of CSF A(42), should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available